30 min
Spotlight: Starpharma’s COVID-19 Nasal Spray for UK & Europe The MTPConnect Podcast
-
- Science
Melbourne based-Starpharma CEO Dr Jackie Fairley joins the MTPConnect Podcast this week to share the full story behind the fast track development of VIRALEZE™, an antiviral nasal spray for COVID-19 just registered in Europe and soon to be available in the EU and UK to complement vaccines and other preventative measures. Jackie shares how MRFF funding from MTPConnect’s Biomedical Translation Bridge (BTB) Program came through at the right time to support the research and development of the spray against important respiratory viruses. She also outlines Starpharma’s work with global pharmaceutical giants to develop new medical products based on dendrimers that are used to improve pharmaceuticals, to reduce toxicities and enhance their performance.
Melbourne based-Starpharma CEO Dr Jackie Fairley joins the MTPConnect Podcast this week to share the full story behind the fast track development of VIRALEZE™, an antiviral nasal spray for COVID-19 just registered in Europe and soon to be available in the EU and UK to complement vaccines and other preventative measures. Jackie shares how MRFF funding from MTPConnect’s Biomedical Translation Bridge (BTB) Program came through at the right time to support the research and development of the spray against important respiratory viruses. She also outlines Starpharma’s work with global pharmaceutical giants to develop new medical products based on dendrimers that are used to improve pharmaceuticals, to reduce toxicities and enhance their performance.
30 min